Actively Recruiting
Phase II Study Comparing AR Blockade Alone Versus AR Blockade with Carotuximab in Men with Metastatic Castration-Resistant Prostate Cancer
Led by Edwin Posadas, MD · Updated on 2026-10-05
116
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the addition of carotuximab to androgen receptor AR blockade therapy in men with metastatic, castration-resistant prostate cancer who have shown progression after AR signaling inhibitor therapy. This Phase II study aims to compare progression-free survival between patients receiving AR blockade alone and those receiving AR blockade combined with carotuximab. The study also assesses adverse events, overall response rates, and benefits for patients resistant to AR blockade. Participants receive AR blockade with Apalutamide or Enzalutamide daily in 28-day cycles. Carotuximab is given intravenously with an initial dose escalation schedule during the first two cycles, followed by monthly doses thereafter. Patients who progress on AR blockade alone may crossover to combination therapy involving carotuximab. The study begins with a safety assessment in the first 10 subjects before proceeding to the full Phase II stage. Throughout the study, participants undergo evaluations based on radiographic and biochemical criteria to monitor disease progression and response. Researchers track progression-free survival, response rates, and adverse events. Participants must agree to contraception use during and for three months after treatment. The study duration extends until disease progression, death, or up to 30 days after treatment ends, with ongoing safety monitoring during and shortly after treatment.
CONDITIONS
Brief Title
Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc
Research Team
C
Clinical Trial Recruitment Navigator
E
Edwin Posadas, MD FACP
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here